MCK

There are companies that shape markets, and there are companies that constitute markets. McKesson Corporation belongs to the second category. As one of three firms that collectively control over 90% of U.S. pharmaceutical distribution, McKesson does not merely participate in the healthcare supply chain. It is the supply chain. Every day, roughly one-third of all pharmaceuticals dispensed in the United States pass through McKesson's distribution network before reaching a patient. This is not a company that competes for market share in any conventional sense. The market, as it functionally exists, was built around companies like McKesson.

Founded in 1833, McKesson is older than most of the pharmaceutical manufacturers whose products it distributes. Its longevity is not accidental. The economics of pharmaceutical wholesale distribution create a structural equilibrium that is extraordinarily difficult to disrupt. Margins are razor-thin, measured in low single-digit percentages, but they sit atop a revenue base that exceeded $300 billion in fiscal year 2025. The business demands massive scale, regulatory compliance infrastructure, cold-chain logistics, controlled substance tracking, and contractual relationships with thousands of manufacturers and tens of thousands of pharmacy locations. No new entrant can replicate this overnight. No existing player outside the Big Three has demonstrated the ability to challenge it.

The central analytical question for McKesson is not whether the moat exists. It does. The question is whether the moat's economic returns can expand, or whether McKesson is structurally capped by the commodity-like nature of drug distribution and the regulatory ceiling that governs its pricing relationships. With the stock trading at $884.28 and a 200-day rate of change of nearly 23%, the market appears to be pricing in more than just distribution. It is pricing in McKesson's evolution toward higher-margin technology and oncology services, a strategic pivot that management has pursued with increasing conviction. Whether that pivot generates durable incremental value, or simply adds complexity to a business that prints cash through logistical dominance, defines the investment case from here.

The L17X insight on McKesson is this: the company's true power does not derive from being the largest distributor. It derives from the fact that its removal would require the reconstruction of the entire U.S. pharmacy ecosystem, including retail chains, hospital systems, government procurement, and specialty pharmacy networks, simultaneously. That is not market share. That is infrastructure.